المؤلفون: Kambez H. Benam, Brian F. Niemeyer

المصدر: Pharmacology & Therapeutics

مصطلحات موضوعية: Drug repurposing, Host-targeting therapies, MSC, mesenchymal stem cell, medicine.disease_cause, TTSP, type II transmembrane serine protease, Mpro, virally encoded main protease of SARS-CoV-2, Pandemic, Nafamostat mesylate, Pharmacology (medical), Coronavirus, COVID-19, coronavirus disease 2019, Drug discovery, Anticoagulant, MERS-CoV, Middle East respiratory syndrome coronavirus, IL1B, interleukin 1B, HIV, human immunodeficiency virus, Drug repositioning, Nrf2, nuclear factor erythroid 2 p45-related factor 2, VSV, vesicular stomatitis virus, medicine.drug_class, IL6, interleukin 6, SARS-CoV, severe acute respiratory syndrome coronavirus, ACE2, angiotensin-converting enzyme 2, Antiviral Agents, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, Virus, Article, RdRp, RNA dependent RNA polymerase, medicine, Humans, Antiviral, Pandemics, Pharmacology, Ang II, angiotensin II, business.industry, SARS-CoV-2, AT1, angiotensin II type 1 receptor, Virus Activation, Anticoagulants, medicine.disease, COVID-19 Drug Treatment, Pneumonia, PD-L1, programmed death-ligand 1, FasL, Fas ligand, COPD, chronic obstructive pulmonary disease, Immunology, Anti-inflammatory, business, CoV, coronaviruses

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efcfcc20bde90ad03f6f6afde92a529c
https://pubmed.ncbi.nlm.nih.gov/34718070